Replies to post #662 on Biotech Values

[DewDiligence]

It’s nice for EXEL that BMY has the confidence to renew the collaboration ahead of time, but these collaborations are not especially profitable for EXEL in the short run. I don’t see EXEL getting above $10 until there is more positive clinical data on the company’s in-house drug candidates. JMHO. Dew